Safety, Pharmacokinetics, and Pharmacodynamics of SHR7280, an Oral Gonadotropin-releasing Hormone Receptor Antagonist, in Healthy Men: a Randomized, Double-blind, Placebo-controlled Phase 1 Study

Overview

Journal BMC Med

Publisher Biomed Central

Specialty General Medicine

Date 2023 Apr 4

PMID 37013610

Authors

Xin Li

FeiFei Sun

Xiaolei Zhang

Pingping Lin

Kai Shen

Yu Shen

Lingyu Ma

Yu Cao

Chenjing Wang

Affiliations

Soon will be listed here.

Abstract

Background: Gonadotropin-releasing hormone (GnRH) antagonists are a promising therapeutic approach for treating hormone-dependent prostate cancer. Currently, the mainstream GnRH antagonists are polypeptide agents administered through subcutaneous injection. In this study, we evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of SHR7280, an oral small molecule GnRH antagonist, in healthy men.

Methods: This phase 1 trial was a randomized, double-blind, placebo-controlled, and dose-ascending study. Eligible healthy men were randomized in a 4:1 ratio to receive either oral SHR7280 tablets or placebo twice daily (BID) for 14 consecutive days. The SHR7280 dose was initiated at 100 mg BID and then sequentially increased to 200, 350, 500, 600, 800, and 1000 mg BID. Safety, PK, and PD parameters were assessed.

Results: A total of 70 subjects were enrolled and received the assigned drug, including 56 with SHR7280 and 14 with placebo. SHR7280 was well-tolerated. The incidence of adverse events (AEs, 76.8% vs 85.7%) and treatment-related AEs (75.0% vs 85.7%), as well as the severity of AEs (moderate AEs, 1.8% vs 7.1%) were similar between the SHR7280 group and placebo group. SHR7280 was rapidly absorbed in a dose-dependent manner, with a median T of each dose group ranging from 0.8 to 1.0 h on day 14 and a mean t ranging from 2.8 to 3.4 h. The PD results demonstrated that SHR7280 exhibited a rapid and dose-proportional suppression of hormones, including LH, FSH, and testosterone, with maximum suppression achieved at doses of 800 and 1000 mg BID.

Conclusions: SHR7280 showed an acceptable safety profile, as well as favorable PK and PD profiles within a dose range of 100 to 1000 mg BID. This study proposes a rationale for further investigation of SHR7280 as a potential androgen deprivation therapy.

Trial Registration: Clinical trials.gov NCT04554043; registered September 18, 2020.

References

Huirne J, Lambalk C . Gonadotropin-releasing-hormone-receptor antagonists. Lancet. 2001; 358(9295):1793-803. DOI: 10.1016/S0140-6736(01)06797-6. View

Conn P, Crowley Jr W . Gonadotropin-releasing hormone and its analogs. Annu Rev Med. 1994; 45:391-405. DOI: 10.1146/annurev.med.45.1.391. View

Nejat R, Rashid H, Bagiella E, Katz A, Benson M . A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. J Urol. 2000; 164(6):1891-4. View

Gilbert S, Kuo Y, Shahinian V . Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States. Urol Oncol. 2009; 29(6):647-53. PMC: 2888908. DOI: 10.1016/j.urolonc.2009.09.004. View

Trachtenberg J, Gittleman M, Steidle C, Barzell W, Friedel W, Pessis D . A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol. 2002; 167(4):1670-4. DOI: 10.1097/00005392-200204000-00021. View

Shore N, Saad F, Cookson M, George D, Saltzstein D, Tutrone R . Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med. 2020; 382(23):2187-2196. DOI: 10.1056/NEJMoa2004325. View

Koechling W, Hjortkjaer R, Tanko L . Degarelix, a novel GnRH antagonist, causes minimal histamine release compared with cetrorelix, abarelix and ganirelix in an ex vivo model of human skin samples. Br J Clin Pharmacol. 2010; 70(4):580-7. PMC: 2950992. DOI: 10.1111/j.1365-2125.2010.03730.x. View

MacLean D, Shi H, Faessel H, Saad F . Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males. J Clin Endocrinol Metab. 2015; 100(12):4579-87. PMC: 4667159. DOI: 10.1210/jc.2015-2770. View

Pickles T, Agranovich A, Berthelet E, Duncan G, Keyes M, Kwan W . Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma. Cancer. 2002; 94(2):362-7. DOI: 10.1002/cncr.10219. View

10.

Ng J, Chwalisz K, Carter D, Klein C . Dose-Dependent Suppression of Gonadotropins and Ovarian Hormones by Elagolix in Healthy Premenopausal Women. J Clin Endocrinol Metab. 2017; 102(5):1683-1691. DOI: 10.1210/jc.2016-3845. View

11.

Moussa M, Papatsoris A, Dellis A, Chakra M, Fragkoulis C . Current and emerging gonadotropin-releasing hormone (GnRH) antagonists for the treatment of prostate cancer. Expert Opin Pharmacother. 2021; 22(17):2373-2381. DOI: 10.1080/14656566.2021.1948012. View

12.

Dearnaley D, Saltzstein D, Sylvester J, Karsh L, Mehlhaff B, Pieczonka C . The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label,.... Eur Urol. 2020; 78(2):184-192. DOI: 10.1016/j.eururo.2020.03.001. View

13.

Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T . EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol. 2016; 71(4):630-642. DOI: 10.1016/j.eururo.2016.08.002. View

14.

Dellis A, Papatsoris A . Therapeutic outcomes of the LHRH antagonists. Expert Rev Pharmacoecon Outcomes Res. 2017; 17(5):481-488. DOI: 10.1080/14737167.2017.1375855. View

15.

Ulloa-Aguirre A, Timossi C . Biochemical and functional aspects of gonadotrophin-releasing hormone and gonadotrophins. Reprod Biomed Online. 2003; 1(2):48-62. DOI: 10.1016/s1472-6483(10)61901-3. View

16.

Smith M, Lee H, McGovern F, Fallon M, Goode M, Zietman A . Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer. 2008; 112(10):2188-94. PMC: 2562782. DOI: 10.1002/cncr.23440. View

17.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

18.

Huggins C, Hodges C . Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972; 22(4):232-40. DOI: 10.3322/canjclin.22.4.232. View

19.

Huhtaniemi I, White R, McArdle C, Persson B . Will GnRH antagonists improve prostate cancer treatment?. Trends Endocrinol Metab. 2008; 20(1):43-50. DOI: 10.1016/j.tem.2008.09.003. View

20.

Klotz L, Boccon-Gibod L, Shore N, Andreou C, Persson B, Cantor P . The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008; 102(11):1531-8. DOI: 10.1111/j.1464-410X.2008.08183.x. View